Last edition
News about "IgA nephropathy "
Otsuka receives FDA accelerated approval for Voyxact in adults with IgA nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the US FDA has granted accelerated approval for Voyxact (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
IgA Nephropathy | 27/11/2025 | By Darshana | 134
Chugai Pharmaceutical to Acquire Renalys Pharma to Accelerate Access to Sparsentan Across Asia
Chugai Pharmaceutical has entered into a definitive stock purchase agreement to acquire Renalys Pharma, a company focused on advancing innovative therapies for chronic kidney disease across Asia.
IgA Nephropathy | 24/10/2025 | By Dineshwori | 322
Renalys Pharma Completes Patient Enrollment for Phase III Trial of Sparsentan in Japan
In April 2024 Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
IgA Nephropathy | 01/02/2025 | By Abha | 549
Novartis Presents Interim Analysis of atrasentan Phase III Data
Novartis has presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN).
IgA Nephropathy | 28/05/2024 | By Aishwarya | 623
Vertex Signs Agreement to Acquire Alpine Immune Sciences
Vertex Pharmaceuticals has signed a definitive agreement with Alpine Immune Sciences, a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
IgA Nephropathy | 11/04/2024 | By Aishwarya | 617
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy